论文部分内容阅读
在过去17年内,有许多用细胞毒药物化疗治疗原发性系统性淀粉样变病人的报遭,但多为个案报告,且没有报告临床有效率。哪一种淀粉样变病人能从治疗中得到最大好处仍不清楚。本文报告用烷化剂为基础的化疗治疗153例原发性系统性淀粉样变的有效率。病人和方法所有病例均经活检证实诊断,除外具有明显多发性骨髓瘤的病例。用马法兰和强的松治疗。马法兰开始剂量是0.15mg/kg/d,分2次服;强的松0.8mg/kg/d,分4次服。7天为1疗程,每
In the past 17 years, there have been many reports of treatment of patients with primary systemic amyloidosis with cytotoxic chemotherapies, but many are case reports and none reported clinical efficiencies. It is unclear which amyloidosis patients will benefit most from treatment. This article reports the efficacy of alkylating agent-based chemotherapy in the treatment of 153 patients with primary systemic amyloidosis. All cases of patients and methods were confirmed by biopsy, with the exception of cases with significant multiple myeloma. Treatment with melphalan and prednisone. The starting dose of melphalan is 0.15mg / kg / d, divided 2 times; prednisone 0.8mg / kg / d, divided into 4 times service. 7 days for a course of treatment, each